Dividend for 2011
| $ | Pence | SEK | Payment date | |
|---|---|---|---|---|
| First interim dividend | 0.85 | 51.9 | 5.33 | 12 September 2010 |
| Second interim dividend | 1.95 | 123.6 | 13.21 | 19 March 2011 |
| Total dividend | 2.80 | 175.5 | 18.54 |
$2.55 Dividend per ordinary share 2010
Distributions to shareholders
| 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|
| Dividend ($ million) | 3,6781 | 3,342 | 2,977 | 2,739 | 2,641 |
| Share re-purchases ($ million) | 6,015 | 2,110 | - | 610 | 4,170 |
Our key products
| In 2011, our top 10 medicines by sales were: | |||
|---|---|---|---|
|
Atacand $1,450m (-6%)(2010: $1,483m; 2009: $1,436m) for hypertension and heart failure |
Crestor $6,622m (+13%)(2010: $5,691m; 2009: $4,502m) for managing cholesterol levels |
Nexium $4,429m (-12%)(2010: $4,969m; 2009: $4,959m) for acid reflux |
Losec/Prilosec $946m (+11%)(2010: $986m; 2009: $946m) for the treatment of acid related diseases |
|
Seloken/Toprol-XL $986m (-20%)(2010: $1,210m; 2009: $1,443m) for hypertension, heart failure and angina |
Seroquel IR $4,338m (+3%)(2010: $4,148m; 2009: $4,171m) for schizophrenia and bipolar disorder |
Seroquel XR $1,490m (+27%)(2010: $1,154m; 2009: $695m) for schizophrenia, bipolar disorder and major depressive disorder |
Symbicort $3,148m (+20%)(2010: $2,746m; 2009: $2,294m) for asthma and chronic obstructive pulmonary disease |
|
Synagis $975m (-6%)(2010: $1,038m; 2009: $1,082m) for for RSV, a respiratory infection in infants |
Zoladex $1,179m (+3%)(2010: $1,115m; 2009: $1,086m) for prostate and breast cancer |
A-Z list of products |
|
Our pipeline
We have: 86 pipeline projects of which 79 are in the clinical phase of development and a further seven are approved or launched.
9 projects in late stage of clinical development, either in Phase III or under regulatory review.
18 out of 33 projects in phase II, III or under regulatory review sourced externally.
We continue to prioritise our resources and focus discovery activities on those diseases within our existing therapy areas where we believe there is the greatest potential to meet patient need through the application of novel science. This continual process of prioritisation is designed to ensure that the projects we have in our pipeline constitute the programmes which we believe are most likely to deliver technical and commercial success.
Research and Development
In 2011 we made a core investment of $5 billion on R&D.
At the end of 2011, our R&D organisation comprised approximately 11,300 people at 14 principal centres in eight countries.
Our R&D organisation continues to evolve to meet the challenges facing our industry by investing in high quality science and harnessing the innovation of our people. We are continuously improving our understanding of mechanisms and targets that will become the foundation for developing and delivering tomorrow’s new medicines. These efforts are undertaken with the highest ethical standards, as we are committed to delivering innovative medicines responsibly.
Our key financials
| $m 2011 | $m 2010 | $m 2009 | $m 2008 | $m 2007 | |
|---|---|---|---|---|---|
| Revenue | 33,591 | 33,269 | 32,804 | 31,601 | 29,559 |
| Core * | |||||
| Operating profit | 13,167 | 13,603 | 13,621 | 10,958 | 9,411 |
| Profit before tax | 12,739 | 13,086 | 12,885 | 10,495 | 9,300 |
| Earnings per share | $7.28 | $6.71 | $6.32 | $5.10 | $4.38 |
| Reported | |||||
| Operating profit | 12,795 | 11,494 | 11,543 | 9,144 | 8,094 |
| Profit before tax | 12,367 | 10,977 | 10,807 | 8,681 | 7,983 |
| Earnings per share | $7.33 | $5.60 | $5.19 | $4.20 | $3.74 |
| Net cash inflow from operating activities | 7,821 | 10,680 | 11,739 | 8,742 | 7,510 |
| Dividends paid | (3,764) | (3,361) | (2,977) | (2,739) | (2,641) |
| Cash returned to shareholders | 9,693 | 6,221 | 3,339 | 3,581 | 6,910 |
* Core financial measures are supplemental non-GAAP measures which management believe enhance understanding of the Company’s performance.
- Fact sheets